← Shenyang Xingqi Pharmaceutical overview

Shenyang Xingqi Pharmaceutical vs Shanghai Fosun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shenyang Xingqi Pharmaceutical Co Ltd (300573.CS)

Q3 2026
▲3

Xingqi's profit jumps, buyback done, pipeline advances despite new rival

  • First-half profit and dividend beat expectations Xingqi's first-half net profit rose 28.5% to 430 million yuan on 20.5% higher revenue, with an 82% gross margin. It will pay a cash dividend of 3 yuan per 10 shares, about 106 million yuan. Strong earnings and cash return support the stock price.

    The interim results and dividend are the core new financial news that directly lift investor confidence and the stock's value.

  • Company completed 100 million yuan buyback in a week Xingqi finished its 80-100 million yuan share buyback plan in about a week, paying the full 100 million yuan by August 4. Buying back its own stock reduces shares outstanding and signals management's confidence, which tends to support the price.

    The buyback is a concrete capital action that shows management's belief in the company and can lift the share price.

  • New eye-drop drug gets clinical trial approval Xingqi received NMPA approval to start clinical trials for SQ-23082 eye drops, a Class 2.1 modified new drug for allergic conjunctivitis itching. No similar product is sold in China or abroad, so success could open a new market and add future revenue.

    This pipeline advance is new technology news that could expand Xingqi's product line and long-term growth.

  • Qilu's atropine application accepted, but Xingqi still leads Qilu Pharmaceutical's application for atropine sulfate eye drops was accepted, adding a potential rival in children's myopia. However, Xingqi remains the only approved product, with 2025 sales up 212% to 603.6 million yuan. Qilu's launch timing is uncertain, so the near-term threat is limited.

    This is the main competitive development that could pressure future pricing, but Xingqi's first-mover advantage currently outweighs it.

August 2026
▲3

Xingqi's profit jumps, buyback done, pipeline advances despite new rival

  • First-half profit and dividend beat expectations Xingqi's first-half net profit rose 28.5% to 430 million yuan on 20.5% higher revenue, with an 82% gross margin. It will pay a cash dividend of 3 yuan per 10 shares, about 106 million yuan. Strong earnings and cash return support the stock price.

    The interim results and dividend are the core new financial news that directly lift investor confidence and the stock's value.

  • Company completed 100 million yuan buyback in a week Xingqi finished its 80-100 million yuan share buyback plan in about a week, paying the full 100 million yuan by August 4. Buying back its own stock reduces shares outstanding and signals management's confidence, which tends to support the price.

    The buyback is a concrete capital action that shows management's belief in the company and can lift the share price.

  • New eye-drop drug gets clinical trial approval Xingqi received NMPA approval to start clinical trials for SQ-23082 eye drops, a Class 2.1 modified new drug for allergic conjunctivitis itching. No similar product is sold in China or abroad, so success could open a new market and add future revenue.

    This pipeline advance is new technology news that could expand Xingqi's product line and long-term growth.

  • Qilu's atropine application accepted, but Xingqi still leads Qilu Pharmaceutical's application for atropine sulfate eye drops was accepted, adding a potential rival in children's myopia. However, Xingqi remains the only approved product, with 2025 sales up 212% to 603.6 million yuan. Qilu's launch timing is uncertain, so the near-term threat is limited.

    This is the main competitive development that could pressure future pricing, but Xingqi's first-mover advantage currently outweighs it.

Latest
▲3

Xingqi's profit jumps, buyback done, pipeline advances despite new rival

  • First-half profit and dividend beat expectations Xingqi's first-half net profit rose 28.5% to 430 million yuan on 20.5% higher revenue, with an 82% gross margin. It will pay a cash dividend of 3 yuan per 10 shares, about 106 million yuan. Strong earnings and cash return support the stock price.

    The interim results and dividend are the core new financial news that directly lift investor confidence and the stock's value.

  • Company completed 100 million yuan buyback in a week Xingqi finished its 80-100 million yuan share buyback plan in about a week, paying the full 100 million yuan by August 4. Buying back its own stock reduces shares outstanding and signals management's confidence, which tends to support the price.

    The buyback is a concrete capital action that shows management's belief in the company and can lift the share price.

  • New eye-drop drug gets clinical trial approval Xingqi received NMPA approval to start clinical trials for SQ-23082 eye drops, a Class 2.1 modified new drug for allergic conjunctivitis itching. No similar product is sold in China or abroad, so success could open a new market and add future revenue.

    This pipeline advance is new technology news that could expand Xingqi's product line and long-term growth.

  • Qilu's atropine application accepted, but Xingqi still leads Qilu Pharmaceutical's application for atropine sulfate eye drops was accepted, adding a potential rival in children's myopia. However, Xingqi remains the only approved product, with 2025 sales up 212% to 603.6 million yuan. Qilu's launch timing is uncertain, so the near-term threat is limited.

    This is the main competitive development that could pressure future pricing, but Xingqi's first-mover advantage currently outweighs it.

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

August 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

Latest
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.